ERBB2 and breast carcinoma: However, in spite of a lack of overall correlation between HER2 amplification and SORLA expression in breast cancer, high SORL1 expression appears to predict poor relapse-free and overall survival specifically within HER2-amplified breast cancer patients (Fig. 5b) according to the in silico biomarker assessment tool38 (http://kmplot.com), which interrogates large datasets (e.g. The Cancer Genome Atlas (TCGA), the European Genome Phenotype Archive (EGA) and the Gene Expression Omnibus (GEO)) in its analysis.